Table 2.
The top 100 papers in cholangiocarcinoma treatments.
| Rank | Paper | TC |
|---|---|---|
| 1 | Valle, J. et al., Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010. 362(14): p. 1273-81. | 1922 |
| 2 | Livraghi, T. et al., Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study. Radiology, 2003. 226(2): p. 441–451. | 959 |
| 3 | Jarnagin, W.R. et al., Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Annals of Surgery, 2001. 234(4): p. 507–517. | 905 |
| 4 | Nakeeb, A. et al., Cholangiocarcinoma - A spectrum of intrahepatic, perihilar, and distal tumors. Annals of Surgery, 1996. 224(4): p. 463–473. | 855 |
| 5 | DeOliveira, M.L. et al., Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution. Annals of Surgery, 2007. 245(5): p. 755–762. | 837 |
| 6 | Schnitzbauer, A.A. et al., Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings. Annals of Surgery, 2012. 255(3): p. 405–414. | 800 |
| 7 | Meng, F.Y. et al., Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 2006. 130(7): p. 2113–2129. | 778 |
| 8 | Wang, Y.Z. et al., Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy. Journal of Clinical Oncology, 2013. 31(9): p. 1188–1195. | 660 |
| 9 | Nakamura, H. et al., Genomic spectra of biliary tract cancer. Nature Genetics, 2015. 47(9): p. 1003-+. | 591 |
| 10 | Endo, I. et al., Intrahepatic cholangiocardnoma - Rising frequency, improved survival, and determinants of outcome after resection. Annals of Surgery, 2008. 248(1): p. 84–96. | 550 |
| 11 | Bismuth, H., R. Nakache, and T. Diamond, Management strategies in resection for hilar cholangiocarcinoma. Annals of Surgery, 1992. 215(1): p. 31–38. | 546 |
| 12 | Farges, O. et al., Portal vein embolization before right hepatectomy - Prospective clinical trial. Annals of Surgery, 2003. 237(2): p. 208–217. | 518 |
| 13 | Borger, D.R. et al., Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist, 2012. 17(1): p. 72–79. | 503 |
| 14 | Neuhaus, P. et al., Extended resections for hilar cholangiocarcinoma. Annals of Surgery, 1999. 230(6): p. 808–818. | 492 |
| 15 | de Jong, M.C. et al., Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. Journal of Clinical Oncology, 2011. 29(23): p. 3140–3145. | 452 |
| 16 | Rea, D.J. et al., Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Annals of Surgery, 2005. 242(3): p. 451–461. | 415 |
| 17 | Ortner, M.E.J. et al., Successful photodynamic therapy for nonresectable cholangiocarcinoma: A randomized prospective study. Gastroenterology, 2003. 125(5): p. 1355–1363. | 396 |
| 18 | Primrose, J.N. et al., Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology, 2019. 20(5): p. 663–673. | 396 |
| 19 | Tse, R.V. et al., Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Clinical Oncology, 2008. 26(4): p. 657–664. | 390 |
| 20 | Abou-Alfa, G.K. et al., Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncology, 2020. 21(5): p. 671–684. | 383 |
| 21 | Nagino, M. et al., Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer - Surgical outcome and long-term follow-up. Annals of Surgery, 2006. 243(3): p. 364–372. | 370 |
| 22 | Hemming, A.W. et al., Preoperative portal vein embolization for extended hepatectomy. Annals of Surgery, 2003. 237(5): p. 686–691. | 334 |
| 23 | Andersen, J.B. et al., Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology, 2012. 142(4): p. 1021-U552. | 330 |
| 24 | Jarnagin, W.R. et al., Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma - Implications for adjuvant therapeutic strategies. Cancer, 2003. 98(8): p. 1689–1700. | 325 |
| 25 | Meyer, C.G., I. Penn, and L. James, Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation, 2000. 69(8): p. 1633–1637. | 325 |
| 26 | Burke, E.C. et al., Hilar cholangiocarcinoma - Patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Annals of Surgery, 1998. 228(3): p. 385–392. | 322 |
| 27 | Javle, M. et al., Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Journal of Clinical Oncology, 2018. 36(3): p. 276-+. | 320 |
| 28 | Lee, J. et al., Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 2012. 13(2): p. 181–188. | 311 |
| 29 | Sia, D. et al., Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. Gastroenterology, 2013. 144(4): p. 829–840. | 306 |
| 30 | Murad, S.D. et al., Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers. Gastroenterology, 2012. 143(1): p. 88-U610. | 292 |
| 31 | Ross, J.S. et al., New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. Oncologist, 2014. 19(3): p. 235–242. | 288 |
| 32 | Arai, Y. et al., Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma. Hepatology, 2014. 59(4): p. 1427–1434. | 287 |
| 33 | De Palma, G.D. et al., Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointestinal Endoscopy, 2001. 53(6): p. 547–553. | 277 |
| 34 | Weber, S.M. et al., Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes. Journal of the American College of Surgeons, 2001. 193(4): p. 384–391. | 277 |
| 35 | Seyama, Y. et al., Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Annals of Surgery, 2003. 238(1): p. 73–83. | 270 |
| 36 | Malka, D. et al., Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncology, 2014. 15(8): p. 819–828. | 263 |
| 37 | Kosuge, T. et al., Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Annals of Surgery, 1999. 230(5): p. 663–671. | 261 |
| 38 | Ebata, T. et al., Hepatectomy with portal vein resection for hilar cholangiocarcinoma - Audit of 52 consecutive cases. Annals of Surgery, 2003. 238(5): p. 720–727. | 259 |
| 39 | Hemming, A.W. et al., Surgical management of hilar cholangiocarcinoma. Annals of Surgery, 2005. 241(5): p. 693–702. | 252 |
| 40 | Abou-Alfa, G.K. et al., Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, 2020. 21(6): p. 796–807. | 251 |
| 41 | Farshidfar, F. et al., Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017. 18(11): p. 2780–2794. | 250 |
| 42 | Pichlmayr, R. et al., Surgical treatment in proximal bile duct cancer - A single-center experience. Annals of Surgery, 1996. 224(5): p. 628–638. | 249 |
| 43 | Philip, P.A. et al., Phase II study of erlotinib in patients with advanced biliary cancer. Journal of Clinical Oncology, 2006. 24(19): p. 3069–3074. | 248 |
| 44 | Knox, J.J. et al., Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. Journal of Clinical Oncology, 2005. 23(10): p. 2332–2338. | 246 |
| 45 | Pitt, H.A. et al., Perihilar cholangiocarcinoma - postoperative radiotherapy does not improve survival. Annals of Surgery, 1995. 221(6): p. 788–798. | 236 |
| 46 | Hong, T.S. et al., Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016. 34(5): p. 460-+. | 234 |
| 47 | De Vreede, I. et al., Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplantation, 2000. 6(3): p. 309–316. | 232 |
| 48 | Vauthey, J.N. et al., Is extended hepatectomy for hepatobiliary malignancy justified? Annals of Surgery, 2004. 239(5): p. 722–730. | 232 |
| 49 | Anderson, C.D. et al., Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2004. 8(1): p. 90–97. | 230 |
| 50 | Goyal, L. et al., Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 2017. 7(3): p. 252–263. | 230 |
| 51 | Borad, M.J. et al., Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. Plos Genetics, 2014. 10(2). | 229 |
| 52 | Ohtsuka, M. et al., Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. British Journal of Surgery, 2002. 89(12): p. 1525–1531. | 229 |
| 53 | Wulf, J. et al., Stereotactic radiotherapy of targets in the lung and liver. Strahlentherapie Und Onkologie, 2001. 177(12): p. 645-+. | 226 |
| 54 | Su, C.H. et al., Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Annals of Surgery, 1996. 223(4): p. 384–394. | 224 |
| 55 | Ortner, M. et al., Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology, 1998. 114(3): p. 536–542. | 221 |
| 56 | Klempnauer, J. et al., Resectional surgery of hilar cholangiocarcinoma: A multivariate analysis of prognostic factors. Journal of Clinical Oncology, 1997. 15(3): p. 947–954. | 220 |
| 57 | Bekaii-Saab, T. et al., Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. Journal of Clinical Oncology, 2011. 29(17): p. 2357–2363. | 219 |
| 58 | Kitagawa, Y. et al., Lymph node metastasis from hilar cholangiocarcinoma: Audit of 110 patients who underwent regional and paraaortic node dissection. Annals of Surgery, 2001. 233(3): p. 385–392. | 218 |
| 59 | Kondo, S. et al., Forty consecutive resections of Hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins - Results of a prospective study. Annals of Surgery, 2004. 240(1): p. 95–101. | 217 |
| 60 | Choi, S.B. et al., The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival. Annals of Surgical Oncology, 2009. 16(11): p. 3048–3056. | 216 |
| 61 | Nagino, M. et al., Hepatectomy With Simultaneous Resection of the Portal Vein and Hepatic Artery for Advanced Perihilar Cholangiocarcinoma An Audit of 50 Consecutive Cases. Annals of Surgery, 2010. 252(1): p. 115–123. | 213 |
| 62 | Zoepf, T. et al., Palliation of nonresectable bile duct cancer: Improved survival after photodynamic therapy. American Journal of Gastroenterology, 2005. 100(11): p. 2426–2430. | 213 |
| 63 | Hyder, O. et al., A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma An Eastern and Western Experience. Jama Surgery, 2014. 149(5): p. 432–438. | 212 |
| 64 | Madariaga, J.R. et al., Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases. Annals of Surgery, 1998. 227(1): p. 70–79. | 208 |
| 65 | Guglielmi, A. et al., Intrahepatic Cholangiocarcinoma: Prognostic Factors After Surgical Resection. World Journal of Surgery, 2009. 33(6): p. 1247–1254. | 206 |
| 66 | Ramanathan, R.K. et al., A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemotherapy and Pharmacology, 2009. 64(4): p. 777–783. | 206 |
| 67 | Witzigmann, H. et al., Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma - Palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Annals of Surgery, 2006. 244(2): p. 230–239. | 206 |
| 68 | Sudan, D. et al., Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. American Journal of Transplantation, 2002. 2(8): p. 774–779. | 204 |
| 69 | Robles, R. et al., Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Annals of Surgery, 2004. 239(2): p. 265–271. | 195 |
| 70 | Steel, A.W. et al., Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointestinal Endoscopy, 2011. 73(1): p. 149–153. | 193 |
| 71 | Valle, J.W. et al., Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumors: a multicentre randomised phase II study - The UK ABC-01 Study. British Journal of Cancer, 2009. 101(4): p. 621–627. | 193 |
| 72 | Polydorou, A.A. et al., Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut, 1991. 32(6): p. 685–689. | 193 |
| 73 | Ben-Josef, E. et al., SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of Clinical Oncology, 2015. 33(24): p. 2617-U57. | 184 |
| 74 | Ribero, D. et al., Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma A Multi-institutional Analysis of 434 Patients. Archives of Surgery, 2012. 147(12): p. 1107–1113. | 184 |
| 75 | Iwatsuki, S. et al., Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. Journal of the American College of Surgeons, 1998. 187(4): p. 358–364. | 184 |
| 76 | Hyder, O. et al., Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery, 2013. 153(6): p. 811–818. | 183 |
| 77 | Miyazaki, M. et al., Combined vascular resection in operative resection for hilar cholangiocarcinoma: Does it work or not? Surgery, 2007. 141(5): p. 581–588. | 182 |
| 78 | Isomoto, H. et al., Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholanglocarcinoma cells. Hepatology, 2005. 42(6): p. 1329–1338. | 181 |
| 79 | Lubner, S.J. et al., Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study. Journal of Clinical Oncology, 2010. 28(21): p. 3491–3497. | 181 |
| 80 | Hezel, A.F. and A.X. Zhu, Systemic therapy for biliary tract cancers. Oncologist, 2008. 13(4): p. 415–423. | 180 |
| 81 | Lee, S.G. et al., Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. Journal of Hepato-Biliary-Pancreatic Sciences, 2010. 17(4): p. 476–489. | 180 |
| 82 | Nathan, H. et al., Trends in survival after surgery for cholangiocarcinoma: A 30-year population-based SEER database analysis. Journal of Gastrointestinal Surgery, 2007. 11(11): p. 1488–1496. | 178 |
| 83 | Hochwald, S.N. et al., Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Archives of Surgery, 1999. 134(3): p. 261–266. | 177 |
| 84 | Javle, M. et al., Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management. Cancer, 2016. 122(24): p. 3838–3847. | 177 |
| 85 | Lowery, M.A. et al., Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical Cancer Research, 2018. 24(17): p. 4154–4161. | 177 |
| 86 | Sano, T. et al., One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Annals of Surgery, 2006. 244(2): p. 240–247. | 176 |
| 87 | Gruenberger, B. et al., Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncology, 2010. 11(12): p. 1142–1148. | 175 |
| 88 | Nagorney, D.M. et al., Outcomes after curative resections of cholangiocarcinoma. Archives of Surgery, 1993. 128(8): p. 871–879. | 175 |
| 89 | Farges, O. et al., Influence of Surgical Margins on Outcome in Patients With Intrahepatic Cholangiocarcinoma A Multicenter Study by the AFC-IHCC-2009 Study Group. Annals of Surgery, 2011. 254(5): p. 824–830. | 172 |
| 90 | Nuzzo, G. et al., Improvement in Perioperative and Long-term Outcome After Surgical Treatment of Hilar Cholangiocarcinoma Results of an Italian Multicenter Analysis of 440 Patients. Archives of Surgery, 2012. 147(1): p. 26–34. | 172 |
| 91 | Graham, R.P. et al., Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Human Pathology, 2014. 45(8): p. 1630–1638. | 171 |
| 92 | Farley, D.R., A.L. Weaver, and D.M. Nagorney, Natural-history of unresected cholangiocarcinoma - patient outcome after noncurative intervention. Mayo Clinic Proceedings, 1995. 70(5): p. 425–429. | 170 |
| 93 | Bengala, C. et al., Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British Journal of Cancer, 2010. 102(1): p. 68–72. | 169 |
| 94 | Nimura, Y. et al., Combined portal-vein and liver resection for carcinoma of the biliary-tract. British Journal of Surgery, 1991. 78(6): p. 727–731. | 169 |
| 95 | Bryant, R. et al., Laparoscopic Liver Resection-Understanding its Role in Current Practice The Henri Mondor Hospital Experience. Annals of Surgery, 2009. 250(1): p. 103–111. | 168 |
| 96 | Inoue, K. et al., Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery, 2000. 127(5): p. 498–505. | 168 |
| 97 | Neuhaus, P. et al., Oncological Superiority of Hilar En Bloc Resection for the Treatment of Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2012. 19(5): p. 1602–1608. | 168 |
| 98 | Wakai, T. et al., Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer, 2005. 103(6): p. 1210–1216. | 167 |
| 99 | Casavilla, F.A. et al., Hepatic resection and transplantation for peripheral cholangiocarcinoma. Journal of the American College of Surgeons, 1997. 185(5): p. 429–436. | 167 |
| 100 | Berr, F. et al., Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival. Hepatology, 2000. 31(2): p. 291–298. | 165 |